A Phase 1b/2a Multicenter, Open-Label, Dose-Escalation Study To Determine The Maximum Tolerated Dose, Assess The Safety, Tolerability, Pharmacokinetics And Efficacy Of CC-220 As Monotherapy And In Combination With Other Treatments In Subjects With Multiple Myeloma Read more
Phase I, Open Label Dose-Escalation Study To Evaluate The Safety, Expansion, Persistence And Clinical Activity Of UCARTCS1A (Allogeneic Engineered T-Cells Expressing Anti-CS1 Chimeric Antigen Receptor), Administered In Patients With Relapsed/Refractory Multiple Myeloma Read more
A Phase 1b/2, Open-Label, Safety And Efficacy Study Of Epcoritamab (GEN3013; Duobody®-CD3 X CD20) In Relapsed/Refractory Chronic Lymphocytic Leukemia Read more
Long-Term Follow-Up Study For Participants Of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells Read more
A Phase II Study Of Venetoclax And Rituximab/Hyaluronidase Human In Relapsed/Refractory CLL Read more
A Phase 2 Open-Label, Multicenter Study Evaluating The Safety And Efficacy Of Axicabtagene Ciloleucel In Combination With Either Rituximab Or Lenalidomide In Subjects With Refractory Large B-Cell Lymphoma (ZUMA-14) Read more
